Global Urea Cycle Disorders (UCD) Treatment Market
完整報告名稱與涵蓋範圍
Global Urea Cycle Disorders (UCD) Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032
報告摘要
According to our (Global Info Research) latest study, the global Urea Cycle Disorders (UCD) Treatment market size was valued at US$ 756 million in 2025 and is forecast to a readjusted size of US$ 1437 million by 2032 with a CAGR of 10.5% during review period.
Urea cycle disorders (UCD) treatment refers to the pharmacological management of inherited metabolic diseases caused by deficiencies in urea-cycle enzymes or related transport proteins. These treatments control acute episodes and support long-term disease management by establishing alternative nitrogen-excretion pathways, activating residual urea-cycle activity, replacing deficient enzyme function or restoring the underlying genetic defect, thereby reducing ammonia and other toxic metabolites, hyperammonemic crises, neurological injury and related hospitalization. Under the pharmaceutical treatment scope, major products include glycerol phenylbutyrate, sodium phenylbutyrate, intravenous sodium phenylacetate and sodium benzoate, carglumic acid, pegylated arginase, as well as investigational gene therapies, mRNA therapies and gene-editing treatments, while low-protein diets, conventional medical foods, dialysis and liver transplantation are excluded. Key upstream inputs include phenylbutyric acid and its derivatives, glycerol, sodium benzoate, carglumic acid API, recombinant cell lines, culture media, purification resins, PEG-modification reagents, plasmids, AAV vectors, nucleotides, lipid nanoparticle materials, sterile excipients and pharmaceutical packaging. Major downstream channels include inherited-metabolic-disease centers, children's hospitals, general hospitals, specialty pharmacies and rare-disease distributors. The market is characterized by a limited patient population, stable long-term treatment demand, high treatment value per patient and substantial development, regulatory and commercialization barriers, with an estimated blended gross margin of approximately 70%–84%.
From the demand perspective, the urea cycle disorders treatment market is expected to maintain steady growth, supported by broader newborn screening, wider use of genetic testing, improved inherited-metabolic-disease care networks and longer patient survival. Better identification of late-onset, mild and atypical cases will increase the number of patients receiving long-term pharmacological treatment. Current demand remains concentrated in nitrogen scavengers and medicines for acute hyperammonemic crises, while subtype-specific therapies for NAGS deficiency, ARG1 deficiency and other conditions will increase treatment depth and value per patient. Greater availability, local production and reimbursement support in emerging markets will also contribute to market expansion.
From the treatment-structure perspective, nitrogen scavengers will remain the foundation of long-term management for most patients in the foreseeable future, although innovation is shifting from metabolic bypass control toward subtype-specific and disease-modifying therapies. Conventional medicines will increasingly compete on palatability, formulation convenience, pediatric suitability, dosing burden and long-term adherence, while enzyme therapies may establish clearer positions in patients with defined enzymatic deficiencies. Gene therapy, mRNA therapy and in vivo gene-insertion technologies are also being developed to restore sustained expression of deficient enzymes and could materially reduce lifelong dependence on nitrogen-scavenger treatment if durable efficacy and acceptable safety are demonstrated.
From the competitive perspective, the commercial market remains concentrated among a limited number of companies with established nitrogen-scavenger brands, rare-disease distribution channels and specialized patient-support systems. The entry of conventional and authorized generics will increase pricing and market-share pressure on premium brands, although products with differentiated formulations, pediatric advantages, subtype-specific indications and strong market-access capabilities may retain meaningful positions. Competition will gradually shift from simple ammonia reduction toward prevention of hyperammonemic crises, improvement of neurological outcomes, reduction of hospitalization and enhancement of quality of life. Companies combining innovative treatment platforms with long-term patient-management capabilities are likely to gain an advantage.
From the risk perspective, individual UCD subtypes have small patient populations and highly variable clinical presentations, making development vulnerable to recruitment difficulties, natural disease fluctuation and complex endpoint design. Gene therapies must still address immune responses, liver-safety concerns, loss of efficacy during pediatric growth and limited repeat-dosing options, while mRNA therapies face challenges associated with repeated intravenous administration and long-term delivery-system tolerability. High-cost one-time treatments will also face close scrutiny regarding affordability, durability and risk-sharing arrangements. Over the longer term, the market is expected to develop into a mixed structure of conventional nitrogen scavengers, subtype-specific medicines and disease-modifying therapies, with long-term efficacy, treatment burden, affordability and lifecycle patient management becoming the main determinants of treatment value.
Report Scope
This report is a detailed and comprehensive analysis for global Urea Cycle Disorders (UCD) Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Urea Cycle Disorders (UCD) Treatment market size and forecasts, in consumption value ($ Million), 2021-2032
Global Urea Cycle Disorders (UCD) Treatment market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Urea Cycle Disorders (UCD) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Urea Cycle Disorders (UCD) Treatment market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Urea Cycle Disorders (UCD) Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Urea Cycle Disorders (UCD) Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Ucyclyd Pharma, Recordati, Immedica Pharma, MPerium, Medunik, Zevra Therapeutics, Mallinckrodt, Lupin, Grand Pharmaceutical Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Urea Cycle Disorders (UCD) Treatment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Nitrogen Scavengers
Urea Cycle Activators
Enzyme Therapies
Other
Market segment by Active Ingredient
Glycerol Phenylbutyrate
Sodium Phenylbutyrate
Sodium Phenylacetate and Benzoate
Carglumic Acid
Other
Market segment by Administration Route
Oral
Intravenous
Subcutaneous
Market segment by Application
Hospitals
Clinic
Other
Market segment by players, this report covers
Amgen
Ucyclyd Pharma
Recordati
Immedica Pharma
MPerium
Medunik
Zevra Therapeutics
Mallinckrodt
Lupin
Grand Pharmaceutical Group
Lee's Pharmaceutical Holdings
Winhealth Pharma Group
Ultragenyx
Arcturus Therapeutics
iECURE
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Urea Cycle Disorders (UCD) Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Urea Cycle Disorders (UCD) Treatment, with revenue, gross margin, and global market share of Urea Cycle Disorders (UCD) Treatment from 2021 to 2026.
Chapter 3, the Urea Cycle Disorders (UCD) Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Urea Cycle Disorders (UCD) Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Urea Cycle Disorders (UCD) Treatment.
Chapter 13, to describe Urea Cycle Disorders (UCD) Treatment research findings and conclusion.
授權報價
| Single User License | $3,480 USD |
| Multi User License | $5,220 USD |
| Corporate Users License | $6,960 USD |
目錄 Table of Contents
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Urea Cycle Disorders (UCD) Treatment by Type
1.3.1 Overview: Global Urea Cycle Disorders (UCD) Treatment Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Type in 2025
1.3.3 Nitrogen Scavengers
1.3.4 Urea Cycle Activators
1.3.5 Enzyme Therapies
1.3.6 Other
1.4 Classification of Urea Cycle Disorders (UCD) Treatment by Active Ingredient
1.4.1 Overview: Global Urea Cycle Disorders (UCD) Treatment Market Size by Active Ingredient: 2021 Versus 2025 Versus 2032
1.4.2 Global Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Active Ingredient in 2025
1.4.3 Glycerol Phenylbutyrate
1.4.4 Sodium Phenylbutyrate
1.4.5 Sodium Phenylacetate and Benzoate
1.4.6 Carglumic Acid
1.4.7 Other
1.5 Classification of Urea Cycle Disorders (UCD) Treatment by Administration Route
1.5.1 Overview: Global Urea Cycle Disorders (UCD) Treatment Market Size by Administration Route: 2021 Versus 2025 Versus 2032
1.5.2 Global Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Administration Route in 2025
1.5.3 Oral
1.5.4 Intravenous
1.5.5 Subcutaneous
1.6 Global Urea Cycle Disorders (UCD) Treatment Market by Application
1.6.1 Overview: Global Urea Cycle Disorders (UCD) Treatment Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Hospitals
1.6.3 Clinic
1.6.4 Other
1.7 Global Urea Cycle Disorders (UCD) Treatment Market Size & Forecast
1.8 Global Urea Cycle Disorders (UCD) Treatment Market Size and Forecast by Region
1.8.1 Global Urea Cycle Disorders (UCD) Treatment Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Urea Cycle Disorders (UCD) Treatment Market Size by Region, (2021-2032)
1.8.3 North America Urea Cycle Disorders (UCD) Treatment Market Size and Prospect (2021-2032)
1.8.4 Europe Urea Cycle Disorders (UCD) Treatment Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Urea Cycle Disorders (UCD) Treatment Market Size and Prospect (2021-2032)
1.8.6 South America Urea Cycle Disorders (UCD) Treatment Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Urea Cycle Disorders (UCD) Treatment Market Size and Prospect (2021-2032)
2 Company Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.1.4 Amgen Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Amgen Recent Developments and Future Plans
2.2 Ucyclyd Pharma
2.2.1 Ucyclyd Pharma Details
2.2.2 Ucyclyd Pharma Major Business
2.2.3 Ucyclyd Pharma Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.2.4 Ucyclyd Pharma Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Ucyclyd Pharma Recent Developments and Future Plans
2.3 Recordati
2.3.1 Recordati Details
2.3.2 Recordati Major Business
2.3.3 Recordati Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.3.4 Recordati Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Recordati Recent Developments and Future Plans
2.4 Immedica Pharma
2.4.1 Immedica Pharma Details
2.4.2 Immedica Pharma Major Business
2.4.3 Immedica Pharma Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.4.4 Immedica Pharma Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Immedica Pharma Recent Developments and Future Plans
2.5 MPerium
2.5.1 MPerium Details
2.5.2 MPerium Major Business
2.5.3 MPerium Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.5.4 MPerium Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 MPerium Recent Developments and Future Plans
2.6 Medunik
2.6.1 Medunik Details
2.6.2 Medunik Major Business
2.6.3 Medunik Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.6.4 Medunik Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Medunik Recent Developments and Future Plans
2.7 Zevra Therapeutics
2.7.1 Zevra Therapeutics Details
2.7.2 Zevra Therapeutics Major Business
2.7.3 Zevra Therapeutics Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.7.4 Zevra Therapeutics Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Zevra Therapeutics Recent Developments and Future Plans
2.8 Mallinckrodt
2.8.1 Mallinckrodt Details
2.8.2 Mallinckrodt Major Business
2.8.3 Mallinckrodt Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.8.4 Mallinckrodt Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Mallinckrodt Recent Developments and Future Plans
2.9 Lupin
2.9.1 Lupin Details
2.9.2 Lupin Major Business
2.9.3 Lupin Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.9.4 Lupin Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Lupin Recent Developments and Future Plans
2.10 Grand Pharmaceutical Group
2.10.1 Grand Pharmaceutical Group Details
2.10.2 Grand Pharmaceutical Group Major Business
2.10.3 Grand Pharmaceutical Group Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.10.4 Grand Pharmaceutical Group Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Grand Pharmaceutical Group Recent Developments and Future Plans
2.11 Lee's Pharmaceutical Holdings
2.11.1 Lee's Pharmaceutical Holdings Details
2.11.2 Lee's Pharmaceutical Holdings Major Business
2.11.3 Lee's Pharmaceutical Holdings Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.11.4 Lee's Pharmaceutical Holdings Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Lee's Pharmaceutical Holdings Recent Developments and Future Plans
2.12 Winhealth Pharma Group
2.12.1 Winhealth Pharma Group Details
2.12.2 Winhealth Pharma Group Major Business
2.12.3 Winhealth Pharma Group Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.12.4 Winhealth Pharma Group Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Winhealth Pharma Group Recent Developments and Future Plans
2.13 Ultragenyx
2.13.1 Ultragenyx Details
2.13.2 Ultragenyx Major Business
2.13.3 Ultragenyx Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.13.4 Ultragenyx Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Ultragenyx Recent Developments and Future Plans
2.14 Arcturus Therapeutics
2.14.1 Arcturus Therapeutics Details
2.14.2 Arcturus Therapeutics Major Business
2.14.3 Arcturus Therapeutics Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.14.4 Arcturus Therapeutics Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Arcturus Therapeutics Recent Developments and Future Plans
2.15 iECURE
2.15.1 iECURE Details
2.15.2 iECURE Major Business
2.15.3 iECURE Urea Cycle Disorders (UCD) Treatment Product and Solutions
2.15.4 iECURE Urea Cycle Disorders (UCD) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 iECURE Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Urea Cycle Disorders (UCD) Treatment Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Urea Cycle Disorders (UCD) Treatment by Company Revenue
3.2.2 Top 3 Urea Cycle Disorders (UCD) Treatment Players Market Share in 2025
3.2.3 Top 6 Urea Cycle Disorders (UCD) Treatment Players Market Share in 2025
3.3 Urea Cycle Disorders (UCD) Treatment Market: Overall Company Footprint Analysis
3.3.1 Urea Cycle Disorders (UCD) Treatment Market: Region Footprint
3.3.2 Urea Cycle Disorders (UCD) Treatment Market: Company Product Type Footprint
3.3.3 Urea Cycle Disorders (UCD) Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Urea Cycle Disorders (UCD) Treatment Consumption Value and Market Share by Type (2021-2026)
4.2 Global Urea Cycle Disorders (UCD) Treatment Market Forecast by Type (2027-2032)
5 Market Size Segment by Application
5.1 Global Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Application (2021-2026)
5.2 Global Urea Cycle Disorders (UCD) Treatment Market Forecast by Application (2027-2032)
6 North America
6.1 North America Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2032)
6.2 North America Urea Cycle Disorders (UCD) Treatment Market Size by Application (2021-2032)
6.3 North America Urea Cycle Disorders (UCD) Treatment Market Size by Country
6.3.1 North America Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2021-2032)
6.3.2 United States Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
6.3.3 Canada Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
6.3.4 Mexico Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
7 Europe
7.1 Europe Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2032)
7.2 Europe Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2032)
7.3 Europe Urea Cycle Disorders (UCD) Treatment Market Size by Country
7.3.1 Europe Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2021-2032)
7.3.2 Germany Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
7.3.3 France Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
7.3.5 Russia Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
7.3.6 Italy Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
8 Asia-Pacific
8.1 Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Urea Cycle Disorders (UCD) Treatment Market Size by Region
8.3.1 Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value by Region (2021-2032)
8.3.2 China Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
8.3.3 Japan Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
8.3.4 South Korea Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
8.3.5 India Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
8.3.7 Australia Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
9 South America
9.1 South America Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2032)
9.2 South America Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2032)
9.3 South America Urea Cycle Disorders (UCD) Treatment Market Size by Country
9.3.1 South America Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2021-2032)
9.3.2 Brazil Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
9.3.3 Argentina Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
10 Middle East & Africa
10.1 Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Urea Cycle Disorders (UCD) Treatment Market Size by Country
10.3.1 Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2021-2032)
10.3.2 Turkey Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
10.3.4 UAE Urea Cycle Disorders (UCD) Treatment Market Size and Forecast (2021-2032)
11 Market Dynamics
11.1 Urea Cycle Disorders (UCD) Treatment Market Drivers
11.2 Urea Cycle Disorders (UCD) Treatment Market Restraints
11.3 Urea Cycle Disorders (UCD) Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Urea Cycle Disorders (UCD) Treatment Industry Chain
12.2 Urea Cycle Disorders (UCD) Treatment Upstream Analysis
12.3 Urea Cycle Disorders (UCD) Treatment Midstream Analysis
12.4 Urea Cycle Disorders (UCD) Treatment Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Active Ingredient, (USD Million), 2021 & 2025 & 2032
Table 3. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 4. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Amgen Company Information, Head Office, and Major Competitors
Table 8. Amgen Major Business
Table 9. Amgen Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 10. Amgen Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Amgen Recent Developments and Future Plans
Table 12. Ucyclyd Pharma Company Information, Head Office, and Major Competitors
Table 13. Ucyclyd Pharma Major Business
Table 14. Ucyclyd Pharma Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 15. Ucyclyd Pharma Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Ucyclyd Pharma Recent Developments and Future Plans
Table 17. Recordati Company Information, Head Office, and Major Competitors
Table 18. Recordati Major Business
Table 19. Recordati Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 20. Recordati Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Immedica Pharma Company Information, Head Office, and Major Competitors
Table 22. Immedica Pharma Major Business
Table 23. Immedica Pharma Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 24. Immedica Pharma Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Immedica Pharma Recent Developments and Future Plans
Table 26. MPerium Company Information, Head Office, and Major Competitors
Table 27. MPerium Major Business
Table 28. MPerium Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 29. MPerium Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. MPerium Recent Developments and Future Plans
Table 31. Medunik Company Information, Head Office, and Major Competitors
Table 32. Medunik Major Business
Table 33. Medunik Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 34. Medunik Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Medunik Recent Developments and Future Plans
Table 36. Zevra Therapeutics Company Information, Head Office, and Major Competitors
Table 37. Zevra Therapeutics Major Business
Table 38. Zevra Therapeutics Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 39. Zevra Therapeutics Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Zevra Therapeutics Recent Developments and Future Plans
Table 41. Mallinckrodt Company Information, Head Office, and Major Competitors
Table 42. Mallinckrodt Major Business
Table 43. Mallinckrodt Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 44. Mallinckrodt Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Mallinckrodt Recent Developments and Future Plans
Table 46. Lupin Company Information, Head Office, and Major Competitors
Table 47. Lupin Major Business
Table 48. Lupin Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 49. Lupin Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Lupin Recent Developments and Future Plans
Table 51. Grand Pharmaceutical Group Company Information, Head Office, and Major Competitors
Table 52. Grand Pharmaceutical Group Major Business
Table 53. Grand Pharmaceutical Group Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 54. Grand Pharmaceutical Group Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Grand Pharmaceutical Group Recent Developments and Future Plans
Table 56. Lee's Pharmaceutical Holdings Company Information, Head Office, and Major Competitors
Table 57. Lee's Pharmaceutical Holdings Major Business
Table 58. Lee's Pharmaceutical Holdings Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 59. Lee's Pharmaceutical Holdings Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Lee's Pharmaceutical Holdings Recent Developments and Future Plans
Table 61. Winhealth Pharma Group Company Information, Head Office, and Major Competitors
Table 62. Winhealth Pharma Group Major Business
Table 63. Winhealth Pharma Group Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 64. Winhealth Pharma Group Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Winhealth Pharma Group Recent Developments and Future Plans
Table 66. Ultragenyx Company Information, Head Office, and Major Competitors
Table 67. Ultragenyx Major Business
Table 68. Ultragenyx Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 69. Ultragenyx Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Ultragenyx Recent Developments and Future Plans
Table 71. Arcturus Therapeutics Company Information, Head Office, and Major Competitors
Table 72. Arcturus Therapeutics Major Business
Table 73. Arcturus Therapeutics Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 74. Arcturus Therapeutics Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Arcturus Therapeutics Recent Developments and Future Plans
Table 76. iECURE Company Information, Head Office, and Major Competitors
Table 77. iECURE Major Business
Table 78. iECURE Urea Cycle Disorders (UCD) Treatment Product and Solutions
Table 79. iECURE Urea Cycle Disorders (UCD) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. iECURE Recent Developments and Future Plans
Table 81. Global Urea Cycle Disorders (UCD) Treatment Revenue (USD Million) by Players (2021-2026)
Table 82. Global Urea Cycle Disorders (UCD) Treatment Revenue Share by Players (2021-2026)
Table 83. Breakdown of Urea Cycle Disorders (UCD) Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 84. Market Position of Players in Urea Cycle Disorders (UCD) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 85. Head Office of Key Urea Cycle Disorders (UCD) Treatment Players
Table 86. Urea Cycle Disorders (UCD) Treatment Market: Company Product Type Footprint
Table 87. Urea Cycle Disorders (UCD) Treatment Market: Company Product Application Footprint
Table 88. Urea Cycle Disorders (UCD) Treatment New Market Entrants and Barriers to Market Entry
Table 89. Urea Cycle Disorders (UCD) Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 90. Global Urea Cycle Disorders (UCD) Treatment Consumption Value (USD Million) by Type (2021-2026)
Table 91. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Share by Type (2021-2026)
Table 92. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Forecast by Type (2027-2032)
Table 93. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2026)
Table 94. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Forecast by Application (2027-2032)
Table 95. North America Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 96. North America Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 97. North America Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 98. North America Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 99. North America Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 100. North America Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 101. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 102. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 103. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 104. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 105. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 106. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 107. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 108. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 109. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 110. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 111. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 112. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value by Region (2027-2032) & (USD Million)
Table 113. South America Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 114. South America Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 115. South America Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 116. South America Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 117. South America Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 118. South America Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 119. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 120. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 121. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 122. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 123. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 124. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 125. Global Key Players of Urea Cycle Disorders (UCD) Treatment Upstream (Raw Materials)
Table 126. Global Urea Cycle Disorders (UCD) Treatment Typical Customers
List of Figures
Figure 1. Urea Cycle Disorders (UCD) Treatment Picture
Figure 2. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Type in 2025
Figure 4. Nitrogen Scavengers
Figure 5. Urea Cycle Activators
Figure 6. Enzyme Therapies
Figure 7. Other
Figure 8. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Active Ingredient, (USD Million), 2021 & 2025 & 2032
Figure 9. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Active Ingredient in 2025
Figure 10. Glycerol Phenylbutyrate
Figure 11. Sodium Phenylbutyrate
Figure 12. Sodium Phenylacetate and Benzoate
Figure 13. Carglumic Acid
Figure 14. Other
Figure 15. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 16. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Administration Route in 2025
Figure 17. Oral
Figure 18. Intravenous
Figure 19. Subcutaneous
Figure 20. Global Urea Cycle Disorders (UCD) Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 21. Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Application in 2025
Figure 22. Hospitals Picture
Figure 23. Clinic Picture
Figure 24. Other Picture
Figure 25. Global Urea Cycle Disorders (UCD) Treatment Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 26. Global Urea Cycle Disorders (UCD) Treatment Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 27. Global Market Urea Cycle Disorders (UCD) Treatment Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 28. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Region (2021-2032)
Figure 29. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Region in 2025
Figure 30. North America Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 31. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 32. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 33. South America Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 34. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 35. Company Three Recent Developments and Future Plans
Figure 36. Global Urea Cycle Disorders (UCD) Treatment Revenue Share by Players in 2025
Figure 37. Urea Cycle Disorders (UCD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 38. Market Share of Urea Cycle Disorders (UCD) Treatment by Player Revenue in 2025
Figure 39. Top 3 Urea Cycle Disorders (UCD) Treatment Players Market Share in 2025
Figure 40. Top 6 Urea Cycle Disorders (UCD) Treatment Players Market Share in 2025
Figure 41. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Share by Type (2021-2026)
Figure 42. Global Urea Cycle Disorders (UCD) Treatment Market Share Forecast by Type (2027-2032)
Figure 43. Global Urea Cycle Disorders (UCD) Treatment Consumption Value Share by Application (2021-2026)
Figure 44. Global Urea Cycle Disorders (UCD) Treatment Market Share Forecast by Application (2027-2032)
Figure 45. North America Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 46. North America Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 47. North America Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 48. United States Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 49. Canada Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 50. Mexico Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 52. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 53. Europe Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 55. France Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 60. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 61. Asia-Pacific Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Region (2021-2032)
Figure 62. China Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 63. Japan Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 64. South Korea Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 65. India Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 66. Southeast Asia Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 67. Australia Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 68. South America Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 69. South America Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 70. South America Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 71. Brazil Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 72. Argentina Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 73. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 74. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 75. Middle East & Africa Urea Cycle Disorders (UCD) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 76. Turkey Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 77. Saudi Arabia Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 78. UAE Urea Cycle Disorders (UCD) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 79. Urea Cycle Disorders (UCD) Treatment Market Drivers
Figure 80. Urea Cycle Disorders (UCD) Treatment Market Restraints
Figure 81. Urea Cycle Disorders (UCD) Treatment Market Trends
Figure 82. Porters Five Forces Analysis
Figure 83. Urea Cycle Disorders (UCD) Treatment Industrial Chain
Figure 84. Methodology
Figure 85. Research Process and Data Source
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Global Info Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們